Robert Friesen

Robert Friesen

Chief Scientific Officer

  • Will join Ablynx as of 1 March 2018
  • Currently:  Senior Vice President, heading the Science and Early Development division at ProQR Therapeutics
  • Previously: Global Head of Biologics Research at Janssen BioTherapeutics

As of 1 March 2018, Dr Friesen will lead the Ablynx’s scientific, research and technology activities.

Dr Friesen has more than 20 years of experience in the biopharmaceutical industry, leading multiple Research and Development (R&D) organisations. Dr Friesen joins Ablynx from ProQR Therapeutics, a clinical stage biotechnology company, where he is currently Senior Vice President, heading the Science and Early Development division. Prior to joining ProQR Therapeutics, Dr Friesen worked at Janssen BioTherapeutics, a Johnson & Johnson Company as Global Head of Biologics Research, where he established an efficient R&D organisation of more than 200 scientists and professionals located in Europe and US; and at the Crucell Vaccine Institute, a Johnson & Johnson Company, as Vice President Preclinical and Clinical Research where he led the team responsible for discovery, production and preclinical development of monoclonal antibodies. Before Crucell Vaccine Institute, he was Head of Preclinical & Early Clinical Development at MorphoSys.

Dr Friesen holds a PhD in biochemistry from the University of Texas and performed postdoctoral research at the University of Groningen.

< Back